Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

50.27USD
12 Nov 2018
Change (% chg)

-- (--)
Prev Close
$50.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
244,951
52-wk High
$82.68
52-wk Low
$33.06

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.33
Market Cap(Mil.): $1,347.79
Shares Outstanding(Mil.): 26.81
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 81.01 29.57
EPS (TTM): -6.75 -- --
ROI: -87.67 -0.53 12.77
ROE: -87.67 -3.22 14.47

Esperion must face investor case over cholesterol drug, court says

A federal appeals court has revived a proposed class action accusing Esperion Therapeutics Inc of misleading investors by falsely stating the U.S. Food and Drug Administration would not require it to conduct a lengthy study before approving a cholesterol drug.

Sep 28 2018

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

Aug 27 2018

UPDATE 1- Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

Aug 27 2018

BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint

* ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT

May 23 2018

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.

May 23 2018

Earnings vs. Estimates